# 1 Prolonged viral shedding as a marker of severity in respiratory syncytial virus

### 2 **bronchiolitis**

С	
Д	Raí André Silva Watanabe <sup>a</sup> PhD Filipe Nishiyama <sup>a</sup> MD
т 5	Larissa Lyra <sup>b</sup> MD Bruno Sanchez Camargo <sup>b</sup> MD Luciano
6	Kleber de Souza Luna <sup>a</sup> PhD, Danielle Dias Conte <sup>a</sup> MSc
7	Ana Helena Perosa <sup>a</sup> DhD, Nancy Cristina Jungueira Bellei <sup>a</sup>
7 8	PhD
9	
10	Affiliations: <sup>a</sup> Clinical Virology Laboratory, Infectious Diseases Unit, Medicine
11	Department, São Paulo Federal University, São Paulo, SP, Brazil: and <sup>b</sup> Hospital
12	São Paulo. São Paulo. SP. Brazil.
13	
14	Address correspondence to: Raí André Silva Watanabe, Clinical Virology Laboratory.
15	Medicine Department, Hospital São Paulo, Rua Pedro de Toledo, 781, Vila Clementino,
16	15° andar frente, 04039-032, São Paulo, SP, Brazil, raiandre@yahoo.com, + 55 11 5576-
17	4848
18	
19	Institutional mailing adresses:
20	Raí André Silva Watanabe: rai.watanabe@unifesp.br
21	Filipe Nishiyama: filipe.nishiyama@unifesp.br
22	Larissa Lyra: larissa.lyra@unifesp.br
23	Bruno Sanchez Camargo: bruno.sanchez@unifesp.br
24	Danielle Dias Conte: dd.conte@unifesp.br
25	Nancy Cristina Junqueira Bellei: nbellei@unifesp.br
26	
27	Email adresses: Deí Andrá Silve Weteneber reiendre@vebee.com
20	Filine Nishiyama: filine nishiyama@gmail.com
29 20	Larissa Lyra: larissalyra93@gmail.com
31	Bruno Sanchez Camargo: sanchez bsc@gmail.com
32	Luciano Kleber de Souza Luna: lksluna@gmail.com
33	Danielle Dias Conte: daniellediasconte@gmail.com
34	Ana Helena Perosa: anaperosa@gmail.com
35	Nancy Cristina Junqueira Bellei: nbellei@uol.com.br
36	
37	Short title: Viral shedding from RSV bronchiolitis
38	
39	Conflict of Interest Disclosures: The authors have no conflicts of interest to
40	declare
41	
42	Abbreviations:
43	ICU Intensive care unit
44 45	LIVE V Invasive mechanical ventilation <b>PSV</b> Proprietory supervised virus
40 46	<b>RT-aPCB</b> Reverse Transcription - quantitative Polymerase Chain Practice
+0	AT-41 CA Reverse Transcription - quantitative i oryinerase Chain Reaction

- 47 **SARS-CoV-2** Severe acute respiratory syndrome coronavirus 2
- 48 49
- **Contributors Statement Page**
- 50 **Raí André Silva Watanabe:** data curation, formal analysis, investigation, project 51 administration, visualization, writing - original draft.
- 52 **Luciano de Souza Luna:** investigation, methodology, validation.
- 53 Danielle Dias Conte, Ana Helena Perosa: investigation.
- 54 Larissa Lyra, Filipe Nishiyama, and Bruno Sanchez Camargo: investigation, formal
- 55 analysis.
- 56 Nancy Cristina Junqueira Bellei: conceptualization, funding acquisition, supervision,
- 57 writing review and editing.
- 58
- 59 Ethics statement: Ethics committee of UNIVERSIDADE FEDERAL DE SAO PAULO
- 60 gave ethical approval for this work under N. 3.009.916 CEP/UNIFESP n. 1082/2018.
- 61 Consent was given from participants legal representatives to take part in the present study.

# 62 Abstract

### 63

# 64 Background and Objectives

Respiratory syncytial virus (RSV) is responsible for most cases of acute viral bronchiolitis (AVB) in childhood. The association of factors such as RSV subtype, viral load, and viral coinfection with severe disease is controversial. The objective is to describe the viral load dynamics of RSV in children under 2 years with AVB, including the first viral load, peak viral load, viral decay, and any possible association with severe disease.

70

# 71 Methods

72 73 inpatients with AVB and confirmed RSV infection were included. Viral load was
73 obtained through nasal swab samples daily during hospitalization and weekly after
74 discharge until absence of detection.

75

# 76 **Results**

44 of the patients were male, the mean age was 5.76 months, and comorbidities were found
in 15 (20.5%) of the patients. 54 (74%) of the patients had the peak viral load between the

4th and the 7th day of symptom onset. The mean duration of viral detection was 12.5 days.

80 There was no association between the first and peak viral load with markers of severe

81 disease. However, association was found between viral persistence exceeding 10 days and

82 the following factors: longer hospitalization period (p=0.009), length of ventilation support

- (p=0.044), length of invasive mechanical ventilation (p=0.035), prolonged requirement of
- nutritional support (p=0.038), and a longer course of antibiotic treatment (p=0.024). Age

85 was inversely correlated with most of the severity outcomes.

86

# 87 Conclusion

B8 Despite the lack of association between RSV viral load values and disease severity, prolonged viral shedding was associated with several adverse outcomes, which can contribute to a better understanding of RSV disease, particularly as several interventions

90 contribute to a better understanding of RSV disease, particul91 are anticipated to become available in the coming years.

92 93

# Prolonged viral shedding as a marker of severity in respiratory syncytial virus bronchiolitis

94

# 95 Introduction

96 Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections and accounts for up to 80% of acute viral bronchiolitis (AVB) in childhood<sup>1,2,3</sup>. Nearly 97 every child under two years of age is infected with the virus<sup>1</sup>, and 2-3% require 98 hospitalization<sup>3</sup>. Recent data from the United States indicates that RSV is responsible for 99 9.3% of all hospitalizations among the pediatric population with an estimate burden of 1.2 100 billion dollars each year<sup>4</sup>. Two multi-site, international case-control studies about 101 102 pneumonia etiology in children under 5 years of age were conducted in the last decade and RSV had the highest etiological fraction on the PERCH study and the second highest on the 103 GABRIEL study<sup>5,6</sup>. 104

105 Up to 30% of AVB cases involve the detection of multiple viruses, and most cases occur 106 within the first six months of life<sup>3,7</sup>. The risk factors for severe AVB includes lower age 107 (specially below 3 months), prematurity, bronchopulmonary dysplasia, congenital heart 108 disease, immunodeficiency, genetic disorders, neurological and neuromuscular disease, 109 tobacco exposure during pregnancy, lack of breastfeeding and male sex <sup>3,7</sup>.

Studies on RSV shedding, and clinical severity vary in methodology, age groups studied, diagnostic criteria, risk factors considered, and definitions of outcomes. Furthermore, there are variations in the timing of viral load measurements and the methods used for quantification<sup>8-13</sup>.

114 New interventions for managing RSV infections, such as vaccines and monoclonal 115 antibodies, have recently been approved<sup>14</sup>. To assess their impact on the dynamics of RSV-116 associated AVB, it is essential to increase the understanding of RSV viral load.

The study's objective was to characterize the dynamics of RSV viral load from the time of hospital admission to the point of viral shedding, encompassing both inpatients and outpatients. Additionally, the study intended to investigate potential associations between viral load, the RSV subgroup type, the detection of multiple viruses, and patient characteristics (such as age, gender, and comorbidities) and their impact on the severity of clinical outcomes.

123

### 124 Materials and Methods

*Study Design*: The study aimed to characterize the dynamics of RSV viral load, tracking it from hospital admission to the point of final viral shedding, in both inpatients and outpatients. In addition, the study sought to investigate potential associations between viral load, the RSV subgroup type, the presence of multiple viruses excluding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and patient characteristics (such as age, gender, and comorbidities) in relation to the severity of clinical outcomes.

131 The inclusion criteria for the study were as follows:

- Hospitalized patients under 2 years of age diagnosed with acute viral bronchiolitis
   and not expected to be discharged within the next 24 hours.
- 134 2. Initial assessment confirming RSV infection through reverse transcription –
   135 quantitative Polymerase Chain Reaction (RT-qPCR).
- 136 The exclusion criteria were:
- 137 1. Loss of follow-up before a viral load sample with no RSV detection.
- 138 2. Patients with less than 3 collected samples.
- 139 3. Detection of SARS-CoV-2 through RT-qPCR for a child included in the pandemic
- 140 period.

141

Data collection: The study utilized a convenience sample of children admitted to the 142 hospital's pediatric service with a clinical diagnosis of AVB. These children underwent 143 144 nasopharyngeal swabs to detect RSV through RT-qPCR. The diagnosis of AVB was made 145 by the attending pediatric physician in accordance with the guidelines of the American Academy of Pediatrics<sup>15</sup>. Nasopharyngeal swab samples were obtained by the team 146 147 coordinator, trained resident physicians, or the on-duty physiotherapist for laboratory confirmation of RSV infection. Samples were collected daily during the period of the 148 infant's hospitalization and weekly after hospital discharge, with the collection stopping 149 150 when no further RSV was detected in two consecutive samples. The day of symptom onset 151 was defined as the first respiratory or systemic symptom of RSV infection: fever, cough, 152 runny nose, nasal obstruction, cyanosis, apnea, respiratory distress or wheezing.

153

154 Laboratory Methods: Each collected swab was preserved in 2.0 mL of sterile lactated 155 Ringer's solution and immediately transported to the virology laboratory for RSV molecular screening on the same day or stored at -80°C until investigation. The RNA of 156 swab samples was purified using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, 157 158 Germany) according to the manufacturer's instructions. Molecular detection of RSV was 159 performed by a duplex quantitative RT-qPCR with TaqMan Fast Virus 1-Step Master Mix 160 reagents (Applied Biosystems, Vilnius, Lithuania). The 20 µL of reaction volume 161 contained 1 µM of each primer and 250 nM of the probe for RSV detection (labeled with FAM dye), aimed at the Matrix gene<sup>16</sup>, and 250 nM of each primer and probe (labeled with 162 VIC dye) for human ribonuclease P gene detection as an internal control<sup>17</sup>. Thermocycling 163 conditions were performed on a 7500 Real-Time PCR System (Applied Biosystems), as 164

165	follow: 50°C for 2 min., 95°C for 20 sec., followed by 45 cycles of 95°C for 15 sec., and
166	55°C for 30 sec. (data collection). The cycle threshold of 35 was adopted as a cut-off for
167	the human ribonuclease P and 38 for the RSV RT-qPCR.
168	
169	Viral load analysis: The viral load was measured from a standard curve generated as
170	described elsewhere <sup>18</sup> , with an efficiency of 100.52%. The viral load was expressed in
171	Log10 RNA copies/mL.
172	
173	RSV Subtype: The protocol of RSV subtyping was performed by Fiocruz laboratory with
174	the sample of the highest viral load of each patient <sup>19</sup> .
175	
176	Influenza and Rhinovirus detection: An in-house real-time PCR was performed to detect
177	Influenza A, B and rhinovirus with AgPath-ID <sup>TM</sup> One-Step RT-PCR Reagents
178	(ThermoFischer) according to the manufacturer's instructions. The primers and probes used
179	for each virus detection have been published elsewhere <sup>20,21</sup> . A positive result was
180	considered with a $Ct < 40$ .
181	
182	Statistics: Sample size calculation was performed using G Power 3.1.9.7, based on an effect
183	size of 0.4, power of 80%, alfa error probability of 5% using a linear regression model with
184	7 predictor variables. The number of patients to achieve statistical significance was 44.
185	Data was stored in Microsoft excel 365 sheets. Statistical analysis was obtained using
186	Jamovi (version 2.3.13) with alfa error probability of 5% and confidence interval of 95%.
187	Graphs were built with Microsoft excel 365 and SPSS 26 <sup>th</sup> edition.
188	Continuous variables were described as mean with standard deviation and median with
189	interquartile range, and categorical variables as frequency rates. The 10-day cutoff for viral
190	persistence as a categorical variable was based on the median number obtained as viral

192	Results were considered statistically significant when $p$ value was below 0,05. Multiple
193	linear regression was used accordingly. $R^2$ was used to report the adequation of the model
194	to the data and for effect size. Two models were performed, according to the equation:
195	$y = \beta 0 + \beta 1.x + \varepsilon$
196	y = dependent variable
197	x = covariates
198	$\beta 0 = intercept$
199	$\beta 1 = angular coefficient$
200	$\epsilon = error$
201	
202	Model A: Dependent variables: (1) viral persistence; (2) peak viral load; (3) first viral load.
203	Covariates: (1) age; (2) sex; (3) RSV subtype; (4) comorbidities; (5) rhinovirus.
204	Model B: Dependent variables (days of each outcome): (1) hospitalization; (2) fever; (3)
205	use of oxygen; (4) ICU; (5) any ventilation support; (6) IMV; (7) additional nutrition
206	support; (8) use of antibiotics. Covariates: (1) age; (2) peak viral load; (3) viral persistence
207	over 10 days; (4) sex; (5) RSV subtype; (6) comorbidities; (7) rhinovirus.
208	

### 209 **Results**

Out of a total of 191 hospitalized patients under 2 years with AVB who were tested for RSV infection, 112 (63,9%) were positive for RSV and 73 patients were enrolled in the study. The main reasons of the exclusion for the 48 patients that had RSV detection were: (1) discharge under 24 hours; (2) hospital transfer before 3 samples collected; (3) refusal to participate. One patient had SARS-CoV-2 detection. In 2019, 40 patients were included, and in 2021, 33 patients were included. A total of 548 nasopharyngeal samples were

collected from the enrolled patients, averaging 7.5 samples per patient. Out of these, 496
(90.5%) were obtained during the hospitalization period and were collected daily. Before
discharge, 42 patients (57.5%) exhibited complete viral clearance.

219

220 *Characteristics of study population:* The characteristics of the study population are outlined in Table 1. Comorbidities were observed in 9 patients with prematurity (12.3%), 3 patients 221 222 with cardiac and neurological diseases (4.1% each), and one patient with one of the 223 following: immunodeficiency, bronchopulmonary dysplasia, hematologic disease, renal 224 disease, and genetic syndrome. Two of the patients had more than one comorbidity. None 225 of the premature infants had a gestational age below 30 weeks (ranging from 30 to 36 226 weeks), and only one received palivizumab. The patient who received palivizumab had 227 down syndrome, bronchopulmonary dysplasia, and cardiac disease (patient number 38 from figure 2). 228

Recurrent wheezing was not considered a comorbidity, and 8 patients in the 2019 cohort had experienced at least one previous wheezing episode. Among the 12 cases with rhinovirus co-infection, lower viral loads and shorter persistence of rhinovirus was observed compared to RSV values of the same patient. The Ct values for rhinovirus RNA detection ranged from 28 to 39.

234

Viral Load Analysis: All patients had their first nasopharyngeal swab samples collected on the first or second day of hospitalization. Upon admission, the mean day of symptom onset was  $5.11 \pm 2.54$ , with a median of 5 (ranging from 4 to 6). Three caregivers reported symptoms lasting for more than 12 days at the time of admission.

The initial viral load in the first sample ranged from 4 to 8.01 log10 copies/ml, with a mean

240 of  $6.03 \pm 1.10$  and a median of 6.34 (ranging from 5.12 to 6.79). Peak viral load varied 241 between 4.14 and 8.01 log10 copies/ml, with a mean of  $6.3 \pm 0.98$  and a median of 6.49 242 (ranging from 5.67 to 6.92). In 40 patients (54.8%), the first viral load was identical to the 243 peak viral load. The time to reach the peak viral load after the onset of symptoms is 244 detailed in Table 2. Individual viral load decay can be observed in Figures 1 to 4, while the distribution of viral 245 246 loads for all patients based on the onset of symptoms is illustrated in Figure 5. 247 The duration of viral shedding (viral persistence) was determined as the last day of RSV 248 detection in relation to symptom onset. The mean viral persistence was  $12.5 \pm 5.72$  days, 249 with a median of 10 days (ranging from 9 to 15 days) and varying from 6 to 33 days. A 250 total of 33 patients (45.2%) exhibited viral persistence exceeding the median of 10 days. To 251 provide a more detailed perspective, viral persistence was further analyzed on a weekly basis, considering that samples were collected every 7 days, as displayed in Table 3. 252 253 No statistically significant associations were found between viral load markers (first viral 254 load, peak viral load, and viral persistence) and the various covariates, including age, 255 gender, RSV subgroup, comorbidities, rhinovirus co-detection, and recurrent wheezing. 256 The complete linear regression analysis for the model A is shown on table 4.

257

Analysis of severity outcomes: Frequency and length of studied outcomes are described on table 5. Severity outcomes were studied as dependent variables of the multiple linear regression. Possible variables of association were analyzed as covariates. Age was inversely correlated with higher hospitalization period (p=0.039), more days of oxygen use (p=0.039) and need for ICU (p=0.045). Patients who experienced viral persistence for more than 10 days were found to have a significant correlation with a longer hospitalization

period (p=0.009), increased days of ventilation support (p=0.044), extended duration of IMV (p=0.035), prolonged requirement for nutritional support (p=0.038), and a longer course of antibiotic treatment (p=0.024). Mean and standard deviation of studied outcomes and p value for patients according to the 10-day RSV shedding are show on table 6. The complete linear regression analysis for model B is shown on table 7.

269

### 270 **Discussion**

271 Our study presents the most extensive longitudinal examination of RSV viral load in AVB 272 patients, with an analysis based on severity outcomes. Despite utilizing a convenience 273 sample over a two-year period, we successfully detected RSV in 64% of AVB patients that 274 were submitted to viral detection. The study spanned two years, with a gap between them 275 due to the outbreak of the SARS-CoV-2 pandemic, which prompted isolation measures and 276 the closure of schools. This was justified by the fact that several other studies reported a delayed RSV outbreak in the first year of SARS-CoV-2 pandemic<sup>22-24</sup>. A previous study 277 from our group described the patients from the pre-pandemic period<sup>25</sup>. Nevertheless, our 278 findings align with the rates reported in existing literature<sup>3,7</sup>. It's worth noting that the 279 pandemic's impact was evident in the second year of the study, with the absence of children 280 281 experiencing recurrent wheezing.

Upon hospital admission, the reported time since symptom onset averaged 5 days, aligning with the point in the disease course described in the literature when symptoms typically worsen<sup>7</sup>.

Our study revealed several findings that were consistent with existing literature. These included a majority of male patients, a higher incidence of the disease among younger patients (particularly those under 6 months of age), and a predominance of RSV subgroup

A<sup>7,26-29</sup>. Notably, the proportion of severe outcomes in our study, such as the need for ICU admission (46.6%) and IMV (24.7%), was significantly higher than previously reported. This could be attributed to the exclusion of patients who were discharged from the hospital early and the specific characteristics of our hospital<sup>7,30</sup>.

292

*Viral load dynamics:* Viral load and viral persistence have been the subject of investigation in several studies aiming to comprehend RSV viral decay. For instance, Takeyama et al. and Hall et al. collected daily RSV samples during hospitalization but did not continue to monitor patients after discharge<sup>9,31</sup>. Takeyama et al. reported similar findings, including the time to reach peak viral load and the absence of an association between viral load and RSV subgroup with disease severity.

In the study conducted by Brint et al.<sup>32</sup>, RSV samples were collected daily throughout the 299 300 hospitalization period and for specific days following discharge, extending up to the 28th 301 day, even when RSV was no longer detectable. In that study, 11.8% of patients exhibited 302 RSV detection for over 1 month, which was a higher rate compared to our findings. The discrepancy in results, including a higher rate of viral load rebound (19.6%) compared to 303 304 our study (12.3%), could potentially be attributed to variations in viral load measurement 305 techniques and the systematic collection of samples even after RSV was no longer 306 detectable. Viral load rebound was defined as a 10-fold increase in the viral load after a nadir, which happened after the 8<sup>th</sup> day of symptom onset, in two consecutive viral loads. 307

Viral load and viral persistence were not found to be associated with any of the patient
characteristics (age, sex, comorbidities), RSV subgroup, or the presence of rhinovirus. This
aligns with findings from other studies<sup>9,32,33</sup>.

311

Severity Outcomes: Age was inversely associated with most severxity outcomes, as widely reported<sup>3,28</sup>. Our study could not find any association between quantitative viral load and severity outcomes. This association is controversial in the literature, with studies showing a positive association<sup>8,11</sup>, inverse association<sup>12,33</sup> and others bringing no association at all<sup>34,35</sup>. Also, RSV subtype was not associated with severity outcomes; some studies corroborate this finding<sup>36,37</sup>, while others associate disease severity with the subgroup A<sup>38,39</sup>.

The primary and original data in our study was the association between viral persistence exceeding 10 days and most severity outcomes. The viral persistence may be a red flag for worsening outcomes and could encourage RSV detection and viral load quantification in patients with prolonged need for hospitalization and critical care. Future studies regarding treatment with antivirals and monoclonal antibodies could also address the benefit in RSV AVB patients with prolonged viral shedding.

324

325 Several limitations were experienced in our study. The accuracy of caregiver-provided 326 information regarding the onset of symptoms, essential for standardizing the viral load curve, may be influenced by various factors, particularly prior upper airway infections, 327 especially given the seasonal nature of respiratory viruses. There was an important loss of 328 329 patients due to hospital transfer, as our hospital ward was not sufficient to hold all the 330 patients during the peak of respiratory viruses' seasonality. We also expected more patients 331 with comorbidities, and for that reason we could not analyze them separately. Additionally, 332 we did not explore the co-detection of other viruses and RSV genotypes, apart from the 333 subgroup. It's important to note that the severity of AVB can be influenced by a multitude of factors related to the virus, the patient, and external variables. Investigating all these 334 factors simultaneously is a challenging in study design. 335

336

# 33**7**. Conclusion

338	Predictors of bronchiolitis severity can be highly complex. In addition to younger age, our
339	study suggests that RSV viral persistence is associated to more severe disease. Further
340	research into the dynamics of viral load in new studies may validate these findings. The
341	information we have provided on viral shedding can contribute to a better understanding of
342	RSV disease, particularly as several interventions, including vaccines, antivirals, and
343	monoclonal antibodies, are anticipated to become available in the coming years.

### References

- 1. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986 Jun;140(6):543-6. doi: 10.1001/archpedi.1986.02140200053026. PMID: 3706232.
- 2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. PMID: 20399493; PMCID: PMC2864404.
- 3. Meissner HC. Viral Bronchiolitis in Children. N Engl J Med. 2016 Jan 7;374(1):62-72. doi: 10.1056/NEJMra1413456.
- 4. Simões EAF. The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis. J Infect Dis. 2022 Aug 15;226(Suppl 2):S143-S147. doi: 10.1093/infdis/jiac211.
- 5. Bénet T, Sánchez Picot V, Messaoudi M, et al. Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network. Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. Clin Infect Dis. 2017 Aug 15;65(4):604-612. doi: 10.1093/cid/cix378.
- Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019 Aug 31;394(10200):757-779. doi: 10.1016/S0140-6736(19)30721-4. Epub 2019 Jun 27. Erratum in: Lancet. 2019 Aug 31;394(10200):736.
- Kyler KE, McCulloh RJ. Current Concepts in the Evaluation and Management of Bronchiolitis. Infect Dis Clin North Am. 2018 Mar;32(1):35-45. doi: 10.1016/j.idc.2017.10.002. Epub 2017 Dec 18.
- 8. El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011 Oct 1;204(7):996-1002. doi: 10.1093/infdis/jir494.
- 9. Takeyama A, Hashimoto K, Sato M, et al. Respiratory syncytial virus shedding by children hospitalized with lower respiratory tract infection. J Med Virol. 2016 Jun;88(6):938-46. doi: 10.1002/jmv.24434. Epub 2015 Dec 1.
- 10. Hijano DR, Brazelton de Cardenas J, Maron G, et al. Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR. PLoS One. 2019 Sep 3;14(9):e0220908. doi: 10.1371/journal.pone.0220908.
- 11. Haddadin Z, Beveridge S, Fernandez K, et al. Respiratory Syncytial Virus Disease Severity in Young Children. Clin Infect Dis. 2021 Dec 6;73(11):e4384-e4391. doi: 10.1093/cid/ciaa1612.
- Brenes-Chacon H, Garcia-Mauriño C, Moore-Clingenpeel M, et al. Agedependent Interactions Among Clinical Characteristics, Viral Loads and Disease Severity in Young Children With Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 Feb 1;40(2):116-122. doi: 10.1097/INF.000000000002914.

- 13. Hartmann K, Liese JG, Kemmling D, et al. Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study). J Infect Dis. 2022 Aug 26;226(3):386-395. doi: 10.1093/infdis/jiac137.
- 14. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8.
- Ralston SL, Lieberthal AS, Meissner HC, et al. American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742. Erratum in: Pediatrics. 2015 Oct;136(4):782.
- 16. Fry AM, Chittaganpitch M, Baggett HC, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS One. 2010 Nov 30;5(11):e15098. doi: 10.1371/journal.pone.0015098.
- 17. Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcriptionpolymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis. 2004 Feb;10(2):311-6. doi: 10.3201/eid1002.030759.
- Cruz JS, de Souza Luna LK, Alves VRG, et al. Viral load of respiratory syncytial virus among children from primary care and hospital settings admitted to a university hospital in Brazil (2009-2013). J Med Virol. 2021 Jun;93(6):3397-3400. doi: 10.1002/jmv.26185. Epub 2020 Sep 30.
- Fröhlich GC, Gregianini TS, Pinheiro FG, et al. LACEN-RS Team. Resurgence of human respiratory syncytial virus during COVID-19 pandemic in Southern Brazil. J Med Virol. 2024 Mar;96(3):e29551. doi: 10.1002/jmv.29551. PMID: 38506236.
- 20. Shu B, Kirby MK, Davis WG, et al. Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2021;27(7):1821-1830. doi: 10.3201/eid2707.210462. PMID: 34152951; PMCID: PMC8237866.
- 21. Gagliardi TB, Goldstein ME, Song D, et al. Rhinovirus C replication is associated with the endoplasmic reticulum and triggers cytopathic effects in an in vitro model of human airway epithelium. PLoS Pathog. 2022 Jan 7;18(1):e1010159. doi: 10.1371/journal.ppat.1010159. PMID: 34995322; PMCID: PMC8741012.
- 22. Varela FH, Scotta MC, Polese-Bonatto M, et al. COVIDa study group. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community. J Glob Health. 2021 Mar 1;11:05007. doi: 10.7189/jogh.11.05007.
- 23. Eden, JS., Sikazwe, C., Xie, R. et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun 13, 2884 (2022). https://doi.org/10.1038/s41467-022-30485-3
- 24. Garg I, Shekhar R, Sheikh AB, et al. Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections. Infect Dis Rep. 2022 Jul 24;14(4):558-568. doi: 10.3390/idr14040059.
- 25. Watanabe RAS, Cruz JS, de Souza Luna LK, et al. Respiratory syncytial virus: viral load, viral decay, and disease progression in children with bronchiolitis. Braz J Microbiol. 2022 Sep;53(3):1241-1247. doi: 10.1007/s42770-022-00742-0. Epub 2022 Apr 1.

- 26. Calvo C, Pozo F, García-García ML, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010 Jun;99(6):883-7. doi: 10.1111/j.1651-2227.2010.01714.x. Epub 2010 Feb 16.
- 27. Mansbach JM, Piedra PA, Teach SJ, et al. MARC-30 Investigators. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012 Aug;166(8):700-6. doi: 10.1001/archpediatrics.2011.1669.
- 28. Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. Int J Mol Sci. 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
- 29. Rodriguez-Fernandez R, Tapia LI, Yang CF, et al. Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. J Infect Dis. 2017 Dec 27;217(1):24-34. doi: 10.1093/infdis/jix543.
- Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. Eur J Pediatr. 2018 Jun;177(6):913-920. doi: 10.1007/s00431-018-3138-6. Epub 2018 Apr 13.
- Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976 Jul;89(1):11-5. doi: 10.1016/s0022-3476(76)80918-3.
- Brint ME, Hughes JM, Shah A, et al. Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants. Pediatr Res. 2017 Nov;82(5):872-880. doi: 10.1038/pr.2017.173. Epub 2017 Aug 9.
- 33. Thwaites RS, Coates M, Ito K, et al. Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. Am J Respir Crit Care Med. 2018 Oct 15;198(8):1074-1084. doi: 10.1164/rccm.201712-2567OC.
- 34. Walsh EE, Wang L, Falsey AR, et al. Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. J Infect Dis. 2018 Jun 20;218(2):208-217. doi: 10.1093/infdis/jiy106.
- 35. Souza AP, Leitão LA, Luisi F, et al. Lack of association between viral load and severity of acute bronchiolitis in infants. J Bras Pneumol. 2016 Jul-Aug;42(4):261-265. doi: 10.1590/S1806-37562015000000241.
- 36. Devincenzo, J. Natural Infection of Infants with Respiratory Syncytial Virus Subgroups A and B: A Study of Frequency, Disease Severity, and Viral Load. Pediatr Res 56, 914–917 (2004). https://doi.org/10.1203/01.PDR.0000145255.86117.6A
- 37. Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. Int J Mol Sci. 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
- 38. Jafri HS, Wu X, Makari D, Henrickson KJ. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department

with lower respiratory tract infection or apnea. Pediatr Infect Dis J. 2013 Apr;32(4):335-40. doi: 10.1097/INF.0b013e318282603a.

39. Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013 Dec;32(12):e437-42. doi: 10.1097/INF.0b013e3182a14407.

Figure 1. RSV viral load decay, patients 1 to 21. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization.

Figure 2. RSV viral load decay, patients 22 to 39. Horizontal line correspond to the cut of viral detection. Vertical lines indicate period of hospitalization.

Figure 3. RSV viral load decay, patients 40 to 55. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strips correspond to intensive care unit period.

Figure 4. RSV viral load decay, patients 56 to 73. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strip correspond to intensive care unit period and red strip to invasive mechanical ventilation period.

Figure 5. RSV viral load of samples from all patients according to symptom onset.



Days after beginning of symptoms









